Effect of supplementation in treatment of type 2 diabetes with Coronary Heart Disease

Effects of Q10 supplementation on insulin resistance, inflammatory factors and biomarkers of oxidative stress in type 2 diabetes with Coronary Heart Disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201502245623N35

Enrollment

Registered

2015-03-06

Start date

2015-03-01

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

?????? ????? ????. Ischaemic heart disease (chronic)

Interventions

Intervention 1: Intervention group: Q10 tablet, 100 mg, daily, for 8 weeks orally. Intervention 2: Control group: Placebo tablet, daily, for 8 weeks orally.

Eligibility

Sex/Gender

All

Age

40 Years to 85 Years

Inclusion criteria

Inclusion criteria: Subjects aged 45-75 years Diagnosed with type 2 diabetes and CVD

Exclusion criteria

Exclusion criteria: Intake of CoQ10 or antioxidant supplements within the last 3 months Acute myocardial infarction within the past 3 months Cardiac surgery within the past 3 months Renal or liver failure

Design outcomes

Primary

Measure	Time frame
Fasting plasma glucose. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Hs-CRP. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.	—

Secondary

Measure	Time frame
Triglycerides. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;HDL-cholesterol. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;Total antioxidant. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Nitric oxide. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;VLDL. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;LDL. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;Malondialdehyde. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.	—

Measure

Time frame

Triglycerides. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;HDL-cholesterol. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;Total antioxidant. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Nitric oxide. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;VLDL. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;LDL. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;Malondialdehyde. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 15, 2026